Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 483 publications
Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.
Journal: Circulation. Population health and outcomes
Published: June 22, 2026
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
Journal: JACC. Heart failure
Published: December 14, 2025
Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.
Journal: JACC. Heart failure
Published: August 31, 2025
GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes.
Journal: JAMA network open
Published: August 11, 2025
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Journal: Diabetes, obesity & metabolism
Published: July 17, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.
Journal: JAMA cardiology
Published: June 04, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
Journal: Cardiovascular diabetology
Published: April 28, 2025
Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase.
Journal: European journal of heart failure
Published: April 24, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
Journal: European journal of heart failure
Published: April 12, 2025
Last Updated: 09/26/2026